The separation, analysis and purification of biomolecules by chromatography can be achieved by chromatography techniques based on ion-exchange, affinity, size-exclusion supports, among others. Such packing materials afford separations of biomolecules of different size from amino acids, and proteins to large macromolecules, such as DNA.
DNA analyses are required for many applications across the health and life sciences industries. Genomic DNA, when extracted, is typically available in small quantities that are not amenable for
use in downstream applications. Therefore, DNA fragments are amplified by Polymerase Chain Reaction (PCR), the method that allows in-vitro DNA synthesis. PCR has become the cornerstone of genomics tools.
PCR-amplified target DNA contains smaller components (nucleotides, primers, etc.), which have to be removed from the amplified DNA. Chiral Technologies has recently acquired Diffinity Genomics, the company that developed novel technology for the purification of nucleic acids. The Diffinity RapidTip® technology provides a method for rapid purification of PCR-amplified DNA fragments, in just one minute, using a pre-packed functional pipette tip. To learn more, click here.
High-throughput post-PCR DNA purification system for improving lab productivity.
Chirality is ubiquitous in biological systems. Of the 20 common α-amino acids, 19 amino acids are chiral. The 19 amino acids are L-enantiomers and are critical for life processes. Amino acids are also of utmost importance for human wellbeing.
Amino acids, specifically unnatural amino acids, play an essential role in drug discovery and development as chiral blocks during organic synthesis of active pharmaceutical ingredients (APIs) as well as in disease diagnostics as potential biomarkers. Analysis of amino acids typically involves identification and quantitation of proteins since amino acid sequences determine properties of proteins. These analytical methods, however, do not address separation and detection of chiral amino acids.
The separation of chiral amino acids demands the availability of specific chiral stationary phases. Chiral Technologies developed novel zwitterionic chiral stationary phases for the separation and analysis of a variety of chiral amino acids and small-chain peptides.
Use of zwitterionic chiral selectors for separation of underivatized zwitterionic molecules
Crown ether chiral selectors for separation amino acids and primary amines
Peptides, as therapeutic agents, offer higher specificity and lower toxicity than small-molecule drugs. The global market for peptide therapeutics is estimated to reach over $25 billion by 2018. Improved peptide synthesis using high-throughput approaches is one of the market drivers. Limitations are poor half-lifetime and in vivo stability, which have to be overcome to render peptides as viable target drugs. Since natural amino acids, which are building blocks of peptides, are L-enantiomers, they can easily be degraded by natural proteases. D-peptides are now used to synthesize peptide chains because the proteases cannot recognize D-amino acids, rendering target peptides more stable.
Effective separations of L- and D-amino acids are important in impurity monitoring during peptide synthesis.